Lakefront Biotherapeutics (LKFT) Profit After Tax (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Profit After Tax for 13 consecutive years, with $16.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 110.0% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $562.4 million (up 616.98% YoY), while the FY2025 annual figure was $373.5 million, up 371.84% from the prior year.
• Profit After Tax fell to $16.3 million in Q1 2026 per LKFT's latest filing, from $910.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $910.5 million in Q4 2025 and bottomed at -$539.1 million in Q3 2025.
• Historically, Profit After Tax has averaged $28.4 million across 5 years, with a median of $16.3 million in 2026.
• On a YoY basis, Profit After Tax climbed as much as 3266.69% in 2025 and fell as far as 2104.51% in 2025.
• Lakefront Biotherapeutics' Profit After Tax stood at -$211.4 million in 2022, then jumped by 189.31% to $188.8 million in 2023, then sank by 85.68% to $27.0 million in 2024, then jumped by 3266.69% to $910.5 million in 2025, then plunged by 98.21% to $16.3 million in 2026.
• Business Quant data shows LKFT's Profit After Tax at $16.3 million in Q1 2026, $910.5 million in Q4 2025, and -$539.1 million in Q3 2025.